Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Please reach out to your J.P. Morgan representative to schedule 1-on-1 meetings with Mr. Sofer and Mr. Levy.The overview presentation will review some of the Company's recent achievements as well as the outlook for upcoming data milestones
概述演示將回顧公司最近的一些成就以及即將到來的數據里程碑的前景
JERUSALEM, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 43rd Annual Healthcare Conference on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET, in San Francisco, CA, and will host institutional investor meetings at the event.
耶路撒冷，2024年12月11日（環球新聞通訊）——Alpha Tau Medical Ltd.（"Alpha Tau"或"公司"）（納斯達克：DRTS，DRTSW），創新的α-輻射癌症療法Alpha DaRt的開發者，今天宣佈首席執行官Uzi Sofer和首席財務官Raphi Levy將在2025年1月16日星期四上午9:45（太平洋時間）/ 下午12:45（東部時間）在加利福尼亞州舊金山的J.P.摩根第43屆年度醫療保健大會上進行公司概述和更新，並在活動中爲機構投資者主持會議。
| Event: | J.P. Morgan 43rd Annual Healthcare Conference |
| Format: | Presentation and 1-on-1 Meetings |
| Date: | January 16, 2025 |
| Time: | 9:45AM PT – 10:25AM PT |
| Location: | Westin St. Francis, San Francisco, CA |
| 事件： | J.P.摩根第43屆年度醫療保健大會 |
| 格式： | 演示和一對一會議 |
| 日期： | 2025年1月16日 |
| 時間： | 太平洋時間9:45 - 10:25 |
| 地點: | 舊金山，威斯汀聖弗朗西斯酒店，加利福尼亞州 |
Webcast: Link located on the "Events & Presentations" page in the Investor Relations section on the Company's website at
網絡直播：鏈接位於公司網站投資者關係部分的「活動與演示」頁面上
Please reach out to your J.P. Morgan representative to schedule 1-on-1 meetings with Mr. Sofer and Mr. Levy.
請聯繫您的摩根大通代表，安排與索弗先生和萊維先生的一對一會議。
About Alpha Tau Medical Ltd.
關於Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
阿爾法塔烏成立於2016年，是一家以色列腫瘤治療公司，致力於阿爾法達特的研究、開發和潛在商業化，以治療實體腫瘤。這項技術最初由特拉維夫大學的伊茨哈克·凱爾森教授和約納·凱薩里教授開發。
About Alpha DaRT
關於阿爾法達特
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Alpha DaRt（擴散α發射體放射治療）旨在通過腫瘤內遞送含鈣-224的來源，實現在固體腫瘤上的高效能和適形α輻射。當鈣衰變時，其短生命的子體將從來源中釋放並擴散，同時發射高能α粒子，目的是摧毀腫瘤。由於α發射原子僅能擴散短距離，Alpha DaRt旨在主要影響腫瘤，並保護周圍的健康組織。
Investor Relations Contact:
IR@alphatau.com
投資者關係聯繫方式：
IR@alphatau.com
譯文內容由第三人軟體翻譯。
